Singulex Obtains $19,000,000 Series E Funding

  • Feed Type
  • Date
    1/14/2009
  • Company Name
    Singulex
  • Mailing Address
    1650 Harbor Bay Parkway Alameda, CA 94502
  • Company Description
    Singulex is an early stage biotechnology company with research and development laboratories in St. Louis and commercial operations in Hayward, California.

    Singulex has obtained exclusive license to all intellectual property around its core technology and has further fortified this position. Our business model builds upon both the immediate and longer term needs in therapeutic discovery/development and eventually human disease management through improved diagnostics.

  • Website
    http://www.singulex.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $19,000,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    Singulex will use the funds from this financing to deploy its product and services in the emerging molecular clinical diagnostic market. Initially, the company will focus on cardiovascular disease risk diagnostics using its assay platform for the biomarker c Troponin I (cTnI), a well-validated marker for cardiac necrosis.
  • M&A Terms
  • Venture Investor
    Jafco Ventures America Inc
  • Venture Investor
    OrbiMed
  • Venture Investor
    Fisk Ventures

Trending on Xconomy